Minimal Residual Disease and Survival Outcomes in Patients With Multiple Myeloma After ASCT and Maintenance With Lenalidomide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
J. Clin. Oncol 2022 Apr 04;[EPub Ahead of Print], RM de Tute, C Pawlyn, DA Cairns, FE Davies, T Menzies, A Rawstron, JR Jones, A Hockaday, R Henderson, G Cook, MT Drayson, MW Jenner, MF Kaiser, WM Gregory, GJ Morgan, GH Jackson, RG OwenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.